Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 32 of 32 publications.

Moss E, Burrell A, Lee J, Reichenbach D, Mitchell S, Yan S, Thiruvillakkat K. Economic and humanistic burden in kidney transplant rejection: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar;24(3):343-52. doi: 10.1080/14737167.2024.2305140

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul;23(6):607-18. doi: 10.1080/14737167.2023.2203915

Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006

Swertz M, van Enckevort E, Oliveira JL, Fortier I, Bergeron J, Thurin NH, Hyde E, Kellmann A, Pajouheshnia R, Sturkenboom M, Cunnington M, Nybo Andersen A-M, Marcon Y, Goncalves G, Gini R. Towards an interoperable ecosystem of research cohort and real-world data catalogues enabling multi-center studies. Yearb Med Inform. 2022 Aug;31(1):262-72. doi: 10.1055/s-0042-1742522

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871

Poulos C, Soliman AM, Tekin S, Agarwal SK. Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Nov 3;1-9. doi: 10.1080/14737167.2021.1832468

Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine treated with prophylactic medications: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-31. doi: 10.1080/14737167.2017.1298444

Kosa KM, Cates S, Godwin S, Chambers E. Barriers to using a food thermometer when cooking poultry at home: results from a national survey. Food Prot Trends. 2017 Mar;37(2):116-25.

Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun 8. doi: 10.1080/14737167.2016.1195688

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.

Chen WH, McLeod L, Nelson LM, Williams VS, Fehnel SE. Quantitative challenges facing patient-centered outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun 14;14(3):379-86.

Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):235-57. doi: 10.1586/14737167.2014.891443

Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):441-6.

Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.

DeMuro CJ, Lewis SA, DiBenedetti DB, Price MA, Fehnel SE. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr 1;12(2):181-7.

Kosa KM, Cates SC, Goodwin SL, Coppings RJ, Speller-Henderson L. Most Americans are not prepared to ensure food safety during power outages and other emergencies. Food Prot Trends. 2011 Jul;31(7):428-36.

McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.

Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb 1;11(1):9-25.

Cates SC, Kosa KM, Karns SA, Godwin S, Chambers D. Consumer storage practices for refrigerated ready-to-eat foods: results of a Web-enabled survey. Food Prot Trends. 2007 Jul;27(7):530-43.

Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Shashidhar KH. Outcomes, impact and behavior associated with acute treatment of migraine. Poster presented at the 16th Migraine Trust International Symposium; November 2006. [abstract] Cephalalgia. 2006 Nov; 26(11):1358-403.

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Kosa KM, Cates SC, Post RC, Canavan J. Consumers' attitudes toward labeling food products with possible allergens. Food Prot Trends. 2004 Aug;24(8):605-11.

Cates SC, Kosa KM, Post RC, Caravan J. Consumers' attitudes toward open dating of USDA-regulated foods. Food Prot Trends. 2004 Feb;24(2):82.

Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.